Provided by Tiger Fintech (Singapore) Pte. Ltd.

ANI Pharmaceuticals

67.61
-0.7500-1.10%
Post-market: 67.610.00000.00%19:17 EDT
Volume:356.16K
Turnover:24.08M
Market Cap:1.47B
PE:-148.16
High:68.49
Open:68.14
Low:67.02
Close:68.36
Loading ...

Q4 2024 ANI Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents
·
01 Mar

ANI Pharmaceuticals Inc (ANIP) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com
·
01 Mar

Ani Pharmaceuticals’ Future Hinges on Ocumension’s Success with ILUVIEN in Asia-Pacific

TIPRANKS
·
01 Mar

Why Is ANI Pharmaceuticals (ANIP) Stock Soaring Today

StockStory
·
01 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Recursion Pharmaceuticals, DoubleVerify Holdings, Praxis Precision Medicines

Reuters
·
28 Feb

ANI Pharmaceuticals Expects Strong Start To 2025, On Back Of Cortrophin Gel And Generics, Lifts Annual Forecast

Benzinga
·
28 Feb

Stock Track | ANI Pharmaceuticals Surges 14.73% on Record Q4 Earnings Fueled by Rare Disease Drug Growth

Stock Track
·
28 Feb

ANI Pharmaceuticals Shares Jump on 4Q Beat, Upgraded 2025 Targets

Dow Jones
·
28 Feb

ANI Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

ANI (ANIP) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
·
28 Feb

BUZZ-ANI Pharma rises as rare-disease drugs drive quarterly results beat

Reuters
·
28 Feb

ANI Pharmaceuticals Shares Jump 15.4% Premarket After Raising 2025 Outlook

THOMSON REUTERS
·
28 Feb

ANI Pharmaceuticals Files Form 8-K with SEC

TIPRANKS
·
28 Feb

ANI: Q4 Earnings Snapshot

Associated Press Finance
·
28 Feb

ANI Pharmaceuticals' Q4 Adjusted Earnings, Revenue Rise; Provides 2025 Outlook

MT Newswires Live
·
28 Feb

ANI Pharmaceuticals Expects 2025 Adjusted EPS Of $6.12-$6.49 Versus Consensus Of $5.56

Benzinga
·
28 Feb